Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783 000
https://www.oxb.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 891
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Stuart Paynter | CFO & Director | 832k | N/A | 1972 |
Dr. Frank Mathias | CEO & Director | N/A | N/A | 1962 |
Dr. James Miskin Ph.D. | Chief Quality & Technical Officer | N/A | N/A | N/A |
Mr. Matthew Treagus | Chief Information Officer | N/A | N/A | N/A |
Sophia Bolhassan | Head of Investor Relations | N/A | N/A | N/A |
Ms. Natalie Louise Walter | General Counsel & Company Secretary | N/A | N/A | 1973 |
Ms. Lisa James | Chief People Officer | N/A | N/A | N/A |
Dr. Kyriacos Mitrophanous Ph.D. | Chief Innovation Officer | N/A | N/A | N/A |
Ms. Kati Hudson | Head of Intellectual Property and Contracts | N/A | N/A | N/A |
Dr. Sebastien Ribault | Chief Commercial Officer | N/A | N/A | N/A |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Oxford BioMedica plc’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 1; Compensation: 10.